1
|
Da Silva F, Saada-Sebag G, Leer AM, Meilhac-Fournier C, Valmary-Degano S, Giovannini D. [Renal synovialosarcoma: What about pyelic cytology to make a diagnosis?]. Ann Pathol 2024; 44:204-209. [PMID: 38342653 DOI: 10.1016/j.annpat.2023.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 12/03/2023] [Accepted: 12/04/2023] [Indexed: 02/13/2024]
Abstract
Synovialosarcoma is a malignant mesenchymal tumor of young adults that occurs in the deep soft tissues, particularly around large joints. When it occurs in more unusual sites, it could present a significant diagnostic challenge. In this case, a 19-year-old girl was treated for a pyloric mass. A pyelic urine cytology performed simultaneously with a pyloric biopsy proved to be a significant element of orientation and perfectly concordant with the histopathological aspect of the pyelic mass after nephrectomy. We report here the first case of renal synovialosarcoma documented in pyelic urine.
Collapse
Affiliation(s)
- Fidélia Da Silva
- Service d'anatomie et de cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - Géraldine Saada-Sebag
- Service d'anatomie et de cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France
| | - Anne Mc Leer
- Service d'anatomie et de cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France; Institute for Advanced Biosciences, CHU de Grenoble-Alpes, université Grenoble-Alpes,Inserm U1209, CNRS UMR 5309, 38000 Grenoble, France
| | | | - Séverine Valmary-Degano
- Service d'anatomie et de cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France; Institute for Advanced Biosciences, CHU de Grenoble-Alpes, université Grenoble-Alpes,Inserm U1209, CNRS UMR 5309, 38000 Grenoble, France.
| | - Diane Giovannini
- Service d'anatomie et de cytologie pathologiques, CHU de Grenoble-Alpes, 38000 Grenoble, France; Université Grenoble-Alpes, TIMC-IMAG, CNRS UMR 5525, La Tronche, France
| |
Collapse
|
2
|
Godfraind C, Coutelier M, Pissaloux D, Forest F, Vandenbos F, Hasselblatt M, Boutonnat J, Coste A, Lantuejoul S, Mc Leer A. Analysis of a pituitary tumour with histological features of central neurocytoma points towards the emergence of a new entity recognizable by a specific epigenetic signature. Neuropathol Appl Neurobiol 2023:e12948. [PMID: 38112166 DOI: 10.1111/nan.12948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 12/10/2023] [Accepted: 12/12/2023] [Indexed: 12/20/2023]
Affiliation(s)
- Catherine Godfraind
- Neuropathology Unit, Clermont-Ferrand University Hospital and UMR 1071 Université Clermont-Auvergne, France
| | - Marie Coutelier
- Sorbonne University, Paris Brain Institute (ICM - Institut du Cerveau), INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Daniel Pissaloux
- Department of Biopathology, Centre Léon Bérard, University of Lyon, CNRS UMR 5286, INSERM U1052, Cancer Research Centre of Lyon (CRCL), Lyon, France
| | - Fabien Forest
- Departments of Pathology and Molecular Biology of Tumors, University Hospital of Saint Etienne, Saint Etienne, France
| | | | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Jean Boutonnat
- Department of Pathology, Grenoble University Hospital, France
| | - Aurélien Coste
- Neurosurgery Department, Clermont-Ferrand University Hospital, France
| | - Sylvie Lantuejoul
- Grenoble Alpes University, Department of Biopathology, Centre Léon Bérard, University of Lyon, CNRS UMR 5286, INSERM U1052, Cancer Research Centre of Lyon (CRCL), Lyon, France
| | - Anne Mc Leer
- Grenoble Alpes University, Molecular Pathology Unit, Department of Pathology, Grenoble University Hospital, France
| |
Collapse
|
3
|
Damiola F, Alberti L, Mansuet-Lupo A, Damotte D, Hofman V, Tixier L, Penault-Llorca F, Rouquette I, Vignaud JM, Cazes A, Forest F, Begueret H, Gibault L, Badoual C, Cayre A, Taranchon-Clermont E, Duc A, Mc Leer A, Lantuejoul S. Usefulness of an RNA extraction-free test for the multiplexed detection of ALK, ROS1, and RET Gene Fusions in Real Life FFPE Specimens of Non-Small Cell Lung Cancers. Expert Rev Mol Diagn 2023; 23:1283-1291. [PMID: 37906110 DOI: 10.1080/14737159.2023.2277367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 10/11/2023] [Indexed: 11/02/2023]
Abstract
BACKGROUND ALK, ROS1 and RET rearrangements occur, respectively, in 5%, 2%, and 1% non-small cell lung cancers (NSCLC). ALK and ROS1 fusion proteins detection by immunohistochemistry (IHC) has been validated for rapid patient screening, but ROS1 fusions need to be confirmed by another technique and no RET IHC test is available for clinical use. RESEARCH DESIGN AND METHODS We report herein the usefulness of the HTG EdgeSeq Assay, an RNA extraction-free test combining a quantitative nuclease protection assay with NGS, for the detection of ALK, ROS1 and RET fusions from 'real-life' small NSCLC samples. A total of 203 FFPE samples were collected from 11 centers. They included 143 rearranged NSCLC (87 ALK, 39 ROS1, 17 RET) and 60 ALK-ROS1-RET negative controls. RESULTS The assay had a specificity of 98% and a sensitivity for ALK, ROS1 and RET fusions of 80%, 94% and 100% respectively. Among the 19 HTG-assay false negative samples, the preanalytical conditions were identified as the major factors impacting the assay efficiency. CONCLUSIONS Overall, the HTG EdgeSeq assay offers comparable sensitivities and specificity than other RNA sequencing techniques, with the advantage that it can be used on very small and old samples collected multicentrically.
Collapse
Affiliation(s)
- Francesca Damiola
- Department of Biopathology, CLCC UNICANCER Léon Bérard, Lyon, France
- Anatomopathology Research Platform and Team Genetics, Epigenetics and Biology of Sarcomas, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Laurent Alberti
- Department of Biopathology, CLCC UNICANCER Léon Bérard, Lyon, France
- Integrated analysis of the dynamics of cancer team, Cancer Research Center of Lyon (CRCL), UMR Inserm 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Audrey Mansuet-Lupo
- Department of Pathology, Groupe Hospitalier Universitaire Paris Centre, Cochin Hospital, APHP.centre, Université Paris Cité, Paris, France
| | - Diane Damotte
- Department of Pathology, Groupe Hospitalier Universitaire Paris Centre, Cochin Hospital, APHP.centre, Université Paris Cité, Paris, France
| | - Véronique Hofman
- Department of Biopathology, Nice University Hospital, Nice, France
| | - Lucie Tixier
- UF of Pathology, Centre Jean Perrin UNICANCER, INSERM UMR1240 IMoST, University Clermont Auvergne, Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- UF of Pathology, Centre Jean Perrin UNICANCER, INSERM UMR1240 IMoST, University Clermont Auvergne, Clermont-Ferrand, France
| | - Isabelle Rouquette
- Department of Biopathology, Toulouse University Hospital, Toulouse, France
| | | | - Aurélie Cazes
- Department of Biopathology, Bichat Hospital, Paris, France
| | - Fabien Forest
- Saint Etienne Department of Pathology University Hospital, Saint Etienne, France
| | - Hugues Begueret
- Department of Biopathology, Bordeaux University Hospital, Bordeaux, France
| | - Laure Gibault
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Européen Georges Pompidou, APHP, Paris Cité University, Paris, France
| | - Cécile Badoual
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Européen Georges Pompidou, APHP, Paris Cité University, Paris, France
| | - Anne Cayre
- UF of Pathology, Centre Jean Perrin UNICANCER, INSERM UMR1240 IMoST, University Clermont Auvergne, Clermont-Ferrand, France
| | | | - Adeline Duc
- Department of Biopathology, CLCC UNICANCER Léon Bérard, Lyon, France
- Anatomopathology Research Platform and Team Genetics, Epigenetics and Biology of Sarcomas, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Anne Mc Leer
- CHU Grenoble Alpes Pathology Department, Institute for Advanced Biosciences UGA/INSERM U1209/CNRS 5309, Grenoble Alpes University, Grenoble, France
- Université Grenoble Alpes, Grenoble, France
| | - Sylvie Lantuejoul
- Department of Biopathology, CLCC UNICANCER Léon Bérard, Lyon, France
- Anatomopathology Research Platform and Team Genetics, Epigenetics and Biology of Sarcomas, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, Lyon, France
- Université Grenoble Alpes, Grenoble, France
| |
Collapse
|
4
|
Mc Leer A, Foll M, Brevet M, Antoine M, Novello S, Mondet J, Cadranel J, Girard N, Giaj Levra M, Demontrond P, Audigier-Valette C, Letouzé E, Lantuéjoul S, Fernandez-Cuesta L, Moro-Sibilot D. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. Lung Cancer 2022; 167:98-106. [PMID: 35183375 DOI: 10.1016/j.lungcan.2022.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 01/04/2022] [Accepted: 01/13/2022] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Among the different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reported in EGFR-mutated lung adenocarcinoma (EGFR-LUAD) patients, histological transformation into small cell carcinoma (SCLC) occurs in 3-14% of resistant cases, regardless of the generation of EGFR-TKI. In recent studies, bi-allelic inactivation of TP53 and RB1 has been identified in a vast majority of transformed SCLCs. However, the molecular mechanisms driving this histologic transformation remain largely unknown, mainly due to the rarity of samples. PATIENTS AND METHODS Out of an initial cohort of 64 patients, tumor tissues of adequate quality and quantity for whole exome sequencing (WES) analysis were available for nine tumors for six patients: paired pre- and post-SCLC transformation samples for three Patients and post-SCLC transformation samples for three other patients. RESULTS Mutational analyses showed concurrent TP53 mutations and Rb pathway alterations in five of the six patients analyzed, confirming their suggested role as predisposing genetic alterations to SCLC transformation. In addition, TERT amplification was detected in four of the six patients and found to be an event acquired during SCLC transformation. Clonal history evolution analyses from the paired LUAD/SCLC samples showed different evolution patterns. In two patients, a large proportion of mutations were present in the most recent common ancestor cell of the initial LUAD and the transformed SCLC clones, whereas in the third patient, few clonal mutations were common between the LUAD and SCLC samples and the ancestor clone that lead to SCLC was present at low frequency in the initial LUAD. CONCLUSION Despite varied clinical presentations and clonal history evolution patterns, in addition to p53 and Rb pathways alterations, TERT amplification emerged as another common genetic mechanism of EGFR-LUAD to SCLC transformation in our cohort, and could represent a candidate therapeutic target in this subset of SCLC tumors.
Collapse
Affiliation(s)
- Anne Mc Leer
- Université Grenoble Alpes, Grenoble, France; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences - Université Grenoble Alpes, Grenoble, France.
| | - Matthieu Foll
- International Agency for Research on Cancer (IARC-WHO), Section of Genetics, Lyon, France
| | - Marie Brevet
- Hospices Civils de Lyon, Institut de pathologie Multisite, Site Est, Bron and Université Claude Bernard Lyon 1, Lyon, France
| | - Martine Antoine
- Service d'Anatomie et Cytologie Pathologique, APHP, Hôpital Tenon, 75020 Paris, France and Theranoscan CRC#4 and Curamus Sorbonne Université, Paris, France
| | - Silvia Novello
- Department of Oncology, AOU San Luigi-Orbassano, University of Turin, Italy
| | - Julie Mondet
- Université Grenoble Alpes, Grenoble, France; Service d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences - Université Grenoble Alpes, Grenoble, France
| | - Jacques Cadranel
- Service de Pneumologie et Oncologie thoracique, APHP, Hôpital Tenon and GRC#4 Theranoscan and Curamus Sorbonne Université, Paris, France
| | | | - Matteo Giaj Levra
- Clinique Hospitalo-Universitaire de Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France
| | | | | | - Eric Letouzé
- Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Université Paris Nord, Functional Genomics of Solid Tumors Laboratory, Equipe Labellisée Ligue Contre le Cancer, F-75006 Paris, France
| | - Sylvie Lantuéjoul
- Université Grenoble Alpes, Grenoble, France; Cancer Research Center Lyon, Centre Léon Bérard, Lyon, France
| | | | - Denis Moro-Sibilot
- Université Grenoble Alpes, Grenoble, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences - Université Grenoble Alpes, Grenoble, France; Clinique Hospitalo-Universitaire de Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France
| |
Collapse
|
5
|
Bargas S, Mc Leer A, Mondet J, Chabre O, Laramas M. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion. Eur J Endocrinol 2022; 186:K5-K8. [PMID: 35118995 DOI: 10.1530/eje-21-0509] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Accepted: 02/04/2022] [Indexed: 11/08/2022]
Abstract
rearrangements represent a very rare genomic abnormality among all cancers but can be detected in thyroid cancer with a non-negligible frequency of 2%. Dramatic clinical responses to therapies targeting NTRK chimeric proteins are now well described in the literature. SQSTM1-NTRK1fusions have not yet been described in a full clinical case report. We report a patient with a papillary thyroid carcinoma harboring this unique rearrangement, with an impressive clinical and radiologic response to larotrectinib, a highly specific inhibitor.
Collapse
Affiliation(s)
- Sophie Bargas
- Grenoble Alpes University, Grenoble, France
- Medical Oncology, Cancer and Blood Diseases Department, Grenoble Alpes University Hospital, Grenoble, France
| | - Anne Mc Leer
- Grenoble Alpes University, Grenoble, France
- Pathology Service, Molecular Pathology Unit, Grenoble Alpes University Hospital, Grenoble, France
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble Alpes University, Grenoble, France
| | - Julie Mondet
- Grenoble Alpes University, Grenoble, France
- Pathology Service, Molecular Pathology Unit, Grenoble Alpes University Hospital, Grenoble, France
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble Alpes University, Grenoble, France
| | - Olivier Chabre
- Grenoble Alpes University, Grenoble, France
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble Alpes University, Grenoble, France
- Endocrinology and Diabetology Service, Grenoble Alpes University Hospital, Grenoble, France
| | - Mathieu Laramas
- Grenoble Alpes University, Grenoble, France
- Medical Oncology, Cancer and Blood Diseases Department, Grenoble Alpes University Hospital, Grenoble, France
| |
Collapse
|
6
|
Mondet J, Lo Presti C, Chevalier S, Bertrand A, Tondeur S, Blanchet S, Mc Leer A, Pernet-Gallay K, Mossuz P. Mitochondria in human acute myeloid leukemia cell lines have ultrastructural alterations linked to deregulation of their respiratory profiles. Exp Hematol 2021; 98:53-62.e3. [PMID: 33689800 DOI: 10.1016/j.exphem.2021.03.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 02/16/2021] [Accepted: 03/02/2021] [Indexed: 11/19/2022]
Abstract
Mitochondria not only are essential for cell metabolism and energy supply but are also engaged in calcium homeostasis and reactive oxygen species generation and play a key role in apoptosis. As a consequence, functional mitochondrial disorders are involved in many human cancers including acute myeloid leukemia (AML). However, very few data are available on the deregulation of their number and/or shape in leukemic cells, despite the evident link between ultrastructure and function. In this context, we analyzed the ultrastructural mitochondrial parameters (number per cell, mitochondria area, number of cristae/mitochondria, cristal thickness) in five leukemia cell lines (HEL, HL60, K562, KG1, and OCI-AML3) together with the functional assay of their respiratory profile. First, we describe significant differences in basal respiration, maximal respiration, ATP production, and spare respiratory capacity between our cell lines, confirming the various respiratory profiles among leukemia subtypes. Second, we highlight that these variations are obviously associated with significant interleukemia heterogeneity of the number and/or shape of mitochondria. For instance, KG1, characterized by the smallest number of mitochondria together with reduced cristal diameter, had a particularly deficient respiratory profile. In comparison, the HEL and K562 cell lines, both with high respiratory profiles, harbored the largest number of mitochondria/cells with high cristal diameters. Moreover, we report that K562, carrying the ASXL1 mutation, presents significant mitochondria-endoplasmic reticulum deficiency reflected by decreases in the numbers of matrix granules and mitochondria-associated endoplasmic reticulum membrane (MAM) and mitochondrial-derived vesicle (MDV) precursors, which are implicated in the regulatory pathways of cell mortality via the processes of mitophagy and calcium homeostasis. Contrarily, HL60 carried high levels of matrix granules and MAMs and had a higher sensitivity to drugs targeting mitochondria (rotenone/antimycin). We confirm the implication of ASXL1 mutation in this mitochondria dysregulation through the study of transcript expression (from 415 patients with public data) involved in three mitochondrial pathways: (1) endoplasmic reticulum-mitochondria contacts (MAMs), (2) matrix granule homeostasis, and (3) MDV precursor production. Our study offers new and original data on mitochondria structural alterations linked to deregulation of respiration profiles in AMLs and some genetic characteristics, suggesting that modifications of mitochondrial shape and/or number in leukemic cells participate in chemoresistance and could be a targeted mechanism to regulate their proliferative potential.
Collapse
Affiliation(s)
- Julie Mondet
- Molecular Pathology Laboratory, Grenoble Alpes University Hospital, Grenoble, France; UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France.
| | - Caroline Lo Presti
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France; Laboratory of Hematology, Grenoble Alpes University Hospital, Grenoble, France
| | - Simon Chevalier
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France; Laboratory of Hematology, Grenoble Alpes University Hospital, Grenoble, France
| | - Anne Bertrand
- UGA/INSERM U1216, Grenoble Institute of Neurosciences, Grenoble, France
| | - Sylvie Tondeur
- Laboratory of Hematology, Grenoble Alpes University Hospital, Grenoble, France
| | - Sandrine Blanchet
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France
| | - Anne Mc Leer
- Molecular Pathology Laboratory, Grenoble Alpes University Hospital, Grenoble, France; UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France
| | | | - Pascal Mossuz
- UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences, Grenoble, France; Laboratory of Hematology, Grenoble Alpes University Hospital, Grenoble, France
| |
Collapse
|
7
|
Petit A, Lantuejoul S, Mc Leer A, Mondet J, Piolat C, Durand C, Moro-Sibilot D, Geoerger B, Vassal G, Sartelet H, Plantaz D. Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. Pediatr Blood Cancer 2021; 68:e28666. [PMID: 32896951 DOI: 10.1002/pbc.28666] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 07/26/2020] [Accepted: 08/06/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Audrey Petit
- Département de pédiatrie, CHU de Grenoble, La Tronche, France
| | - Sylvie Lantuejoul
- Département de biopathologie, Centre Léon Berard, CNR Mesopath, Université Grenoble Alpes, Saint-Martin-d'Hères, France
| | - Anne Mc Leer
- Service d'anatomie et cytologie pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, La Tronche, France.,UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-Université Grenoble Alpes, Saint-Martin-d'Hères, France
| | - Julie Mondet
- Service d'anatomie et cytologie pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, La Tronche, France.,UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-Université Grenoble Alpes, Saint-Martin-d'Hères, France
| | - Christian Piolat
- Département de chirurgie Pédiatrique, CHU de Grenoble, La Tronche, France
| | - Chantal Durand
- Département de radiologie Pédiatrique, CHU de Grenoble, La Tronche, France
| | - Denis Moro-Sibilot
- UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-Université Grenoble Alpes, Saint-Martin-d'Hères, France.,Service Hospitalo Universitaire de physiologie et pneumologie, CHU de Grenoble, La Tronche, France
| | - Birgit Geoerger
- Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Saint-Aubin, France
| | - Gilles Vassal
- Direction de la recherche clinique, Institut Gustave Roussy, Villejuif, France
| | - Hervé Sartelet
- Service d'anatomie et cytologie pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, La Tronche, France.,UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-Université Grenoble Alpes, Saint-Martin-d'Hères, France
| | | |
Collapse
|
8
|
Toffart AC, Asfari S, Mc Leer A, Reymond E, Jankowski A, Moro-Sibilot D, Stephanov O, Ghelfi J, Lantuejoul S, Ferretti GR. Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing. Lung Cancer 2020; 140:93-98. [PMID: 31901769 DOI: 10.1016/j.lungcan.2019.12.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 12/17/2019] [Accepted: 12/18/2019] [Indexed: 01/17/2023]
Abstract
OBJECTIVES Bone is a common location for lung cancer metastasis. Clinicians are often reluctant to biopsy bone metastases, as they are known to require a decalcification process that damages nucleic acids, which makes it incompatible with molecular testing. We performed this study to assess the diagnostic performance of histopathology and molecular testing of computed tomography (CT)-guided percutaneous bone biopsies of lytic bone lesions during the initial assessment or during the progression of lung cancer. MATERIALS AND METHODS This retrospective study included all patients suspected of having or known to have primary lung cancer and CT-guided percutaneous bone biopsies of lytic bone from January 2010 to June 2017. The main judgment criterion was the diagnostic performance of the pathological analysis. Secondary endpoints were the diagnostic performance of molecular testing and incidence of complications. RESULTS Fifty patients were included. The yield of CT-guided percutaneous bone biopsies for pathological analysis was 100 %, allowing for a diagnosis of certainty in all cases. The percentage of tumor cells in samples was higher than the 20 % threshold in 83.9 % of cases. The yield of molecular analysis was 94.6 %. A mutation was found in 60 % of cases; most frequently in KRAS (Kirsten rat sarcoma viral oncogene homolog) (28.6 %) and EGFR (epidermal growth factor receptor) (14.3 %). The complication rate was 2 %, i.e. a minor undrained pneumothorax. CONCLUSION CT-guided percutaneous biopsies of lytic bone is associated with a very low complication rate and high diagnostic performance for histopathology and mutation testing.
Collapse
Affiliation(s)
- Anne-Claire Toffart
- Unité d'oncologie thoracique, Service de pneumologie, CS 10217, 38043 Grenoble, France; INSERM U 1209 IAB, la Tronche, 38700, France
| | - Stéphane Asfari
- Service de radiologie diagnostique et interventionnelle, CS 10217, 38043 Grenoble, France
| | - Anne Mc Leer
- INSERM U 1209 IAB, la Tronche, 38700, France; pathologie moléculaire, Institut de Biologie et de Pathologie, CS 10217, 38043 Grenoble, France
| | - Emilie Reymond
- Service de radiologie diagnostique et interventionnelle, CS 10217, 38043 Grenoble, France
| | - Adrien Jankowski
- Service de radiologie diagnostique et interventionnelle, CS 10217, 38043 Grenoble, France
| | - Denis Moro-Sibilot
- Unité d'oncologie thoracique, Service de pneumologie, CS 10217, 38043 Grenoble, France; INSERM U 1209 IAB, la Tronche, 38700, France
| | - Olivier Stephanov
- anatomopathologie, Institut de Biologie et de Pathologie, CS 10217, 38043 Grenoble, France
| | - Julien Ghelfi
- Service de radiologie diagnostique et interventionnelle, CS 10217, 38043 Grenoble, France
| | - Sylvie Lantuejoul
- Plateforme Anapath Recherche Synergie Lyon Cancer-Est, Département de Recherche Translationnelle et d'Innovations Centre de Lutte Contre le Cancer UNICANCER Léon Bérard, 28 rue Laënnec, 69008 Lyon, France
| | - Gilbert R Ferretti
- INSERM U 1209 IAB, la Tronche, 38700, France; Service de radiologie diagnostique et interventionnelle, CS 10217, 38043 Grenoble, France.
| |
Collapse
|
9
|
Mondet J, Laurin D, Lo Presti C, Jacob MC, Meunier M, Giraudon E, Lefebvre C, Berthier S, Leer AM, Park S, Mossuz P. Increased S100A8 expression in bone marrow plasma by monocytic cells from acute myeloid leukemia patients. Hematol Oncol 2020; 38:114-118. [PMID: 31904882 DOI: 10.1002/hon.2707] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 12/06/2019] [Accepted: 12/16/2019] [Indexed: 11/06/2022]
Affiliation(s)
- Julie Mondet
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Molecular Pathology Laboratory, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - David Laurin
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Etablissement Français du Sang, La Tronche, France
| | - Caroline Lo Presti
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France
| | | | - Mathieu Meunier
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Department of Clinical Hematology, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Emmanuelle Giraudon
- Department of Biological Hematology, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Christine Lefebvre
- Oncohematology Laboratory, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Sylvie Berthier
- Flow Cytometry Platform, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Anne Mc Leer
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Molecular Pathology Laboratory, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Sophie Park
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Department of Clinical Hematology, Centre Hospitalier Grenoble Alpes, Grenoble, France
| | - Pascal Mossuz
- Institute for Advanced Biosciences, University Grenoble Alpes /INSERM U1209/CNRS 5309, Grenoble, France.,Department of Biological Hematology, Centre Hospitalier Grenoble Alpes, Grenoble, France
| |
Collapse
|
10
|
Albin N, Mc Leer A, Sakhri L. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?]. Bull Cancer 2018; 105:375-396. [PMID: 29501208 DOI: 10.1016/j.bulcan.2018.01.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 11/22/2017] [Accepted: 01/06/2018] [Indexed: 01/09/2023]
Abstract
In recent years, high-throughput sequencing techniques have been developed for cancerology and many clinical trials are currently structured around biomarkers that can guide specific treatment choices. This approach is characteristic of precision medicine, which is actually a concept initiated several decades ago with, for example, retinoic acid in promyelocytic leukemia. This paper will review the different types of molecular alterations and « -omics » biological analyses, bioinformatics tools, coupled drug/biomarkers already validated, the ethical issues of whole genomic sequencing of an individual as part of an inclusion in a clinical trial and finally the first results of precision medicine trials. The AcSé crizotinib program, supported by the Inca (french Cancer National Institute), is emblematic of a success of this personalized medicine illustrated by 4 points: the discovery of a cohort of patients with lung cancer with a ROS1 rearrangement characteristic of a sensitivity to crizotinib, a rapid availability of this innovation through the implementation of a temporary recommendation for use (ANSM), the obtention of a conditional marketing authorization by the pharmaceutical industry and finally, financial assumption of responsibility by French social security (HAS), despite preliminary and non-comparative data. In the case of cancers refractory to standard chemotherapy, and regarding our system of access to drugs illustrated by the PROFILER clinical trial, this approach allows the access to a therapeutic drug targeting specific biomarkers only in 7% of patients included. This does not bode well for efficient treatment and even less for survival. Allowing patients to be included in trials that identify molecular targets by molecular screening, and not being able to propose the drug of interest is a traumatic event for those patients who live in the hope of an immediate future. In refractory disease we must rethink precision medicine in a more humanistic vision for our patients and not only in a dimension of medico-industrial promotion. The implementation of a new multi-drug/multi-molecular target program could address this issue.
Collapse
Affiliation(s)
- Nicolas Albin
- Groupe hospitalier mutualiste de Grenoble, institut de cancérologie Daniel-Hollard, 8, rue Docteur-Calmette, 38028 Grenoble cedex 1, France.
| | - Anne Mc Leer
- Université Grenoble-Alpes, CHU de Grenoble, département d'anatomie et de cytologie pathologiques, unité fonctionnelle de pathologie moléculaire, pôle biologie, 38043 Grenoble cedex 9, France
| | - Linda Sakhri
- Groupe hospitalier mutualiste de Grenoble, institut de cancérologie Daniel-Hollard, 8, rue Docteur-Calmette, 38028 Grenoble cedex 1, France
| |
Collapse
|